↓ Skip to main content

Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group

Overview of attention for article published in Journal of Clinical Oncology, November 2005
Altmetric Badge

Mentioned by

f1000
1 research highlight platform

Citations

dimensions_citation
153 Dimensions

Readers on

mendeley
83 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group
Published in
Journal of Clinical Oncology, November 2005
DOI 10.1200/jco.2005.01.2781
Pubmed ID
Authors

Christer Sederholm, Gunnar Hillerdal, Kristina Lamberg, Karl Kölbeck, Monika Dufmats, Ronny Westberg, Sulochana R. Gawande

Abstract

This phase III study compared overall survival in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when treated with single-agent gemcitabine versus gemcitabine/carboplatin. Secondary objectives were to compare response, time to progression, toxicity, and quality of life.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 2%
United Kingdom 1 1%
Australia 1 1%
Spain 1 1%
Unknown 78 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 18%
Other 14 17%
Student > Ph. D. Student 12 14%
Student > Master 10 12%
Lecturer 5 6%
Other 15 18%
Unknown 12 14%
Readers by discipline Count As %
Medicine and Dentistry 47 57%
Agricultural and Biological Sciences 6 7%
Nursing and Health Professions 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Social Sciences 2 2%
Other 5 6%
Unknown 17 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2006.
All research outputs
#15,233,109
of 22,649,029 outputs
Outputs from Journal of Clinical Oncology
#16,656
of 19,837 outputs
Outputs of similar age
#123,230
of 145,675 outputs
Outputs of similar age from Journal of Clinical Oncology
#161
of 176 outputs
Altmetric has tracked 22,649,029 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 19,837 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.2. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 145,675 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 176 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.